Search Results
Oct 06, 2025, 09:00 ET Clario and the University of Oxford's NeuroMetrology Lab Advance Parkinson's Disease Research with the Opal® Wearable Sensor System
falls, which represent a significant cause of disability and reduced quality of life in PD patients. Findings from Professor Antoniades' team demonstrate the high potential of movement analysis in PD research and pave the way for predictive and preventive healthcare. In a
More news about: Clario
Oct 06, 2025, 09:00 ET Groundbreaking Study Demonstrates Cala TAPS™ Therapy Reduces Hand Tremor in Essential Tremor Patients by Directly Modulating Brain Activity
Local Coverage Criteria. Cala continues to advocate on behalf of patients with ET and PD to secure additional coverage and reimbursement in Medicare Advantage and commercial payor plans. About
More news about: Cala Health
Oct 06, 2025, 07:00 ET Compugen to Present at SITC 2025
first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development
More news about: Compugen Ltd.
Oct 05, 2025, 15:33 ET Loneliness accelerates motor decline in older adults living with parkinsonism
HONOLULU, Oct. 5, 2025 /PRNewswire/ -- People with Parkinson's disease (PD) often experience isolation, leading to loneliness. However, new research has revealed that not only is this well-established connection a two-way street,
More news about: International Parkinson and Movement Disorder Society
Oct 05, 2025, 15:14 ET Cycling fast to slow Parkinson's: High-rate exercise regimen results in lower rate of motor symptom progression
trial (CYCLE-II), researchers evaluated the efficacy of a 12-month home-based high-intensity exercise intervention in slowing PD progression among people with mild-to-moderate PD (N=256). Individuals assigned to the intervention were prescribed stationary cycling for 45 minutes three times a week, with
More news about: International Parkinson and Movement Disorder Society
Oct 05, 2025, 14:04 ET Cell therapy shows promising motor improvements and safety in Parkinson's disease
PD has long been considered an appropriate candidate for cell replacement therapy due to the loss of dopaminergic neurons in the midbrain, especially within the substantia nigra. The loss of these neurons leads to the characteristic motor and non-motor symptoms of PD, and a progressively
More news about: International Parkinson and Movement Disorder Society
Oct 03, 2025, 10:00 ET HanchorBio Announces Acceptance of HCB301 Abstract for Poster Presentation at SITC 2025 Annual Meeting
Presentation Details The accepted abstract, titled "A Novel Tri-Specific Fc Fusion Protein Targeting PD-L1, CD47, and TGFβ Remodels the Tumor Microenvironment and Enhance Anti-Tumor Immunity", will be presented on Saturday, November 8, 2025.
More news about: HanchorBio Inc.
Oct 03, 2025, 09:00 ET Mitsubishi Tanabe Pharma America to Present New Data on Investigational ND0612 at the 2025 International Congress of Parkinson's Disease and Movement Disorders®
/PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four poster presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the 2025 International Congress of Parkinson's Disease and Movement Disorders®, being held October 5-9 in Honolulu, HI.
More news about: Mitsubishi Tanabe Pharma America
Oct 03, 2025, 05:00 ET Glioblastomas Affect Much More Than Just the Brain
erosion—but one of them (zoledronic acid) also fueled tumor progression in one type of glioblastoma. Both drugs also blocked the beneficial effects of anti-PD-L1, an immunotherapy drug that boosts levels of tumor-fighting T cells. The Nature Neuroscience paper is titled "Brain
More news about: Montefiore Einstein Comprehensive Cancer Center
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
kinase inhibitor discovered by Eisai, plus pembrolizumab (KEYTRUDA®), Merck's (known as MSD outside of the United States and Canada) anti-PD-1 therapy, versus treatment of physician's choice for patients with advanced endometrial carcinoma. The presentation will feature 5-year overall survival
More news about: Eisai Inc.
Oct 02, 2025, 08:00 ET Roadrunner announces its AI-Powered P&D Platform Virtually Eliminates Missed Pickups to Redefine Pickup Reliability in LTL
multimedia:https://www.prnewswire.com/news-releases/roadrunner-announces-its-ai-powered-pd-platform-virtually-eliminates-missed-pickups-to-redefine-pickup-reliability-in-ltl-302573255.html
More news about: Roadrunner
Oct 01, 2025, 17:31 ET CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight
pembrolizumab demonstrated a manageable safety profile and promising efficacy in patients with metastatic melanoma who had previously progressed on anti–PD-1 and anti–CTLA-4 therapies, showing objective responses and notable disease control. Pfizer's PF-06835375,
More news about: DelveInsight Business Research, LLP
Sep 30, 2025, 17:31 ET HPV-Positive Oropharyngeal Cancer Market Poised for Strong Growth by 2034, Driven by Rising Incidence and Treatment Innovation | DelveInsight
cell carcinoma (HNSCC). Despite the progress made with PD-1 inhibitors, their effectiveness remains limited by resistance mechanisms, including immunosuppressive tumor microenvironments and immune escape pathways, particularly in patients with low PD-L1 expression or those who have received prior chemotherapy.
More news about: DelveInsight Business Research, LLP
Sep 30, 2025, 10:50 ET Dialysis Equipment Market to Reach US$ 19.14 billion by 2031 at CAGR of 5.9% | Business Market Insights
Technologies raised $20 million in Series B funding to support its dialysis technology. The Singapore-based company designed Awak PD as a wearable and ultraportable peritoneal dialysis (PD) system. It offers patients the freedom to undergo dialysis at home and anywhere on the go. It helps to overcome the challenge
More news about: Business Market Insights
Sep 30, 2025, 10:04 ET Jersey City's Franklin School Named World's Most Innovative School
address global-scale problems. Faculty Professional Development Continuum: Teachers dedicate 100 minutes each week in Franklin's PD program to advanced pedagogy, sharpening their craft and inspiring students' deep immersion in authentic, future-focused learning.
More news about: Franklin School
Sep 30, 2025, 10:01 ET Peritoneal Dialysis Equipment Market to Reach US$4.09 Billion by 2031 at 6.6% CAGR | Business Market Insights
component of this will be "PD-first" or "PD-favored" policies that will dictate that PD should be the first and preferred treatment modality for clinically appropriate patients. The costs of care associated with PD are lower than those of in-center hemodialysis (HD) because PD does not require expensive
More news about: Business Market Insights
Sep 29, 2025, 22:39 ET Conquiste cada curva con el Toyota GR Corolla 2026
Sistema precolisión con detección de peatones: el sistema precolisión con detección de peatones (PCS w/PD) está diseñado para ayudar a detectar un vehículo, peatón, ciclista o motociclista y proporcionar una advertencia de colisión frontal sonora o visual
More news about: Toyota Motor North America
Sep 29, 2025, 14:15 ET Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics
consistent, reproducible, and scalable GMP-compliant processes. The Celligent GMP platform addresses autologous iPSC-derived production and Celligent PD enables predictive allogeneic process development, as well as tissue engineering and artificial organ applications.
More news about: Cell X Technologies, Inc
Sep 29, 2025, 13:48 ET Vantage Market Research: Global Companion Diagnostics Market Size & Share to Surpass USD 31.75 Billion by 2035, Growing at a CAGR 11.75% | Powering Precision Medicine, Targeted Therapies and Next-Gen Drug Development
Value Creation Opportunities Oncology Leadership: PD-L1, BRCA, and HER2 testing leading adoption in targeted cancer therapies. Chronic & Rare Diseases:
More news about: Vantage Market Research
Sep 29, 2025, 07:00 ET BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
patients with recurrent GBM. The objective of this part is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy. Data from the Phase 1 part of the trial is anticipated in H1 2027. The Phase 2a expansion part of the
More news about: BioLineRx Ltd.
Sep 29, 2025, 06:35 ET Expert Systems Inc., a leading drug discovery accelerator, proudly announces the Series A funding and launch of Mondego Bio, an emerging immuno-oncology company headquartered at Biocant Park in Cantanhede, Portugal.
remain one of the greatest unmet needs in medicine," said Dr. Tudor Oprea, CEO of Expert Systems Inc. "By integrating predictive ADMET and PK/PD modeling with in-silico and in vitro new-approach methodologies (NAMs), we gave Mondego Bio a decisive edge — identifying high-potential PTPN2 inhibitors
More news about: Expert Systems, Inc.
Sep 29, 2025, 06:00 ET AllRock Bio Presents Phase 1 Data for Lead Program, ROC-101, at the ERS Congress
absorbed, and its half-life supports once-daily dosing. Effective target engagement: Pharmacodynamic (PD) and biomarker data demonstrated a dose-dependent decrease in ROCK1 and ROCK2 activity. Superior exposure
More news about: AllRock Bio
Sep 25, 2025, 20:47 ET Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
the payload, this innovative program is designed to convert "cold tumors" into "hot tumors," offering a novel treatment option for solid tumors where PD-1 monotherapy has limited efficacy. The program is currently at the preclinical stage, with IND submission planned for the second half of 2026. As
More news about: Jacobio Pharma
Sep 25, 2025, 10:03 ET CrossWind Technologies' Valcour Cloud™ CAD/RMS Named Public Safety Solution of 2025 by GovCIO Outlook
able to continue responding to calls for service with zero delay," said Deputy Chief Larry Eastman of Barre City PD. Hours later, as Montpelier's own PSAP dispatch center flooded, both agencies relocated to higher ground and resumed
More news about: CrossWind Technologies, Inc.
Sep 25, 2025, 09:03 ET Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson's Disease
clinical trial of ANPD001, the company's personalized dopaminergic neuronal precursor cell (DANPC) therapy for moderate to advanced Parkinson's disease (PD).
More news about: Aspen Neuroscience, Inc.